Zimmer Biomet Holdings (ZBH) seems to be one of the most promising stocks to buy right now in the medical device sector. The company's recent acquisition of Paragon 28 and Monogram Technologies extends its footprint in autonomous solutions and robotics. With top orthopedic surgeons joining the ZBH team, they are poised to shape the future of musculoskeletal care. Recent insider trading and hedge fund activity indicates high confidence in the company. ZBH's dividend resilience and stronger cash flows make it an attractive pick for long-term investors. Despite some fluctuation in the company's stock market performance, underlying earnings have consistently grown over the last five years. Whether the stock will climb or sink is still to be seen, yet the company's ability to beat earnings and revenue estimates in Q2, along with a upbeat earnings forecast, presents a positive outlook. However, despite an improved outlook, ZBH faces significant tariff uncertainty, which led to a momentary drop in their stock price. ZBH continues to show innovation, attracting both retail and institutional investors.
Zimmer Biomet Holdings ZBH News Analytics from Wed, 13 Nov 2024 08:00:00 GMT to Sat, 30 Aug 2025 10:29:28 GMT -
Rating 6
- Innovation 8
- Information 9
- Rumor -3
